Cargando…
Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
BACKGROUND: The aim of the study was to evaluate the efficacy of nicorandil and alprostadil on myocardial protection in patients undergoing elective percutaneous coronary intervention (PCI). METHODS: In this prospective, single-blinded, randomized controlled study, 90 consecutive patients scheduled...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052047/ https://www.ncbi.nlm.nih.gov/pubmed/33847683 http://dx.doi.org/10.1097/MD.0000000000025551 |
_version_ | 1783679852631556096 |
---|---|
author | Zhang, Weifeng Dai, Jinjie Zheng, Xiaowen Xu, Ke Yang, Xiaoxiao Shen, Lan Wang, Xiaolei Hao, Ziyong Qiu, Xingbiao Jiang, Lisheng Shi, Hongyu Shen, Linghong He, Ben |
author_facet | Zhang, Weifeng Dai, Jinjie Zheng, Xiaowen Xu, Ke Yang, Xiaoxiao Shen, Lan Wang, Xiaolei Hao, Ziyong Qiu, Xingbiao Jiang, Lisheng Shi, Hongyu Shen, Linghong He, Ben |
author_sort | Zhang, Weifeng |
collection | PubMed |
description | BACKGROUND: The aim of the study was to evaluate the efficacy of nicorandil and alprostadil on myocardial protection in patients undergoing elective percutaneous coronary intervention (PCI). METHODS: In this prospective, single-blinded, randomized controlled study, 90 consecutive patients scheduled for elective PCI for de novo coronary lesions were assigned to the nicorandil, alprostadil, and nitroglycerin groups in a 1:1:1 ratio. Drugs were administered intracoronary via a targeted perfusion microcatheter. The primary endpoint was the thrombolysis in myocardial infarction (TIMI) myocardial perfusion frame count (TMPFC). Additionally, the corrected TIMI frame count (cTFC), TIMI myocardial perfusion grade (TMPG), and incidence of periprocedural myocardial injury (PMI) were assessed. RESULTS: Both nicorandil and alprostadil were significantly effective in reducing TMPFC (114.6 ± 33.7 vs 93.4 ± 30.9, P = .016; 114.3 ± 34.3 vs 94.7 ± 33.3, P = .029, respectively). Similar findings were observed in the improvement of cTFC (20.3 ± 10.5 vs 13.5 ± 5.0, P = .003; 20.2 ± 7.4 vs 15.2 ± 5.2, P = .003, respectively) and percentage of TMPG 3 (100% vs 82.8%, P = .052; 83.3% vs 96.7%, P = .196, respectively); whereas, nitroglycerin produced a limited effect on TMPFC (114.4 ± 30.9 vs 112.1 ± 31.9, P = .739), cTFC (19.4 ± 7.2 vs 19.3 ± 7.2, P = .936), and percentage of TMPG 3 (86.7% vs 86.7%, P = 1.000). No significant difference was found in the incidence of PMI (16.7% vs 16.0% vs 27.6%, P = .537), though it was comparatively lower in the nicorandil and alprostadil groups. Furthermore, the intracoronary administration of nicorandil and alprostadil had a mild effect on blood pressure and heart rate. CONCLUSIONS: The intracoronary administration of nicorandil and alprostadil via a targeted perfusion microcatheter was more effective in improving myocardial perfusion in patients undergoing elective PCI than nitroglycerin. |
format | Online Article Text |
id | pubmed-8052047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-80520472021-04-19 Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial Zhang, Weifeng Dai, Jinjie Zheng, Xiaowen Xu, Ke Yang, Xiaoxiao Shen, Lan Wang, Xiaolei Hao, Ziyong Qiu, Xingbiao Jiang, Lisheng Shi, Hongyu Shen, Linghong He, Ben Medicine (Baltimore) 3400 BACKGROUND: The aim of the study was to evaluate the efficacy of nicorandil and alprostadil on myocardial protection in patients undergoing elective percutaneous coronary intervention (PCI). METHODS: In this prospective, single-blinded, randomized controlled study, 90 consecutive patients scheduled for elective PCI for de novo coronary lesions were assigned to the nicorandil, alprostadil, and nitroglycerin groups in a 1:1:1 ratio. Drugs were administered intracoronary via a targeted perfusion microcatheter. The primary endpoint was the thrombolysis in myocardial infarction (TIMI) myocardial perfusion frame count (TMPFC). Additionally, the corrected TIMI frame count (cTFC), TIMI myocardial perfusion grade (TMPG), and incidence of periprocedural myocardial injury (PMI) were assessed. RESULTS: Both nicorandil and alprostadil were significantly effective in reducing TMPFC (114.6 ± 33.7 vs 93.4 ± 30.9, P = .016; 114.3 ± 34.3 vs 94.7 ± 33.3, P = .029, respectively). Similar findings were observed in the improvement of cTFC (20.3 ± 10.5 vs 13.5 ± 5.0, P = .003; 20.2 ± 7.4 vs 15.2 ± 5.2, P = .003, respectively) and percentage of TMPG 3 (100% vs 82.8%, P = .052; 83.3% vs 96.7%, P = .196, respectively); whereas, nitroglycerin produced a limited effect on TMPFC (114.4 ± 30.9 vs 112.1 ± 31.9, P = .739), cTFC (19.4 ± 7.2 vs 19.3 ± 7.2, P = .936), and percentage of TMPG 3 (86.7% vs 86.7%, P = 1.000). No significant difference was found in the incidence of PMI (16.7% vs 16.0% vs 27.6%, P = .537), though it was comparatively lower in the nicorandil and alprostadil groups. Furthermore, the intracoronary administration of nicorandil and alprostadil had a mild effect on blood pressure and heart rate. CONCLUSIONS: The intracoronary administration of nicorandil and alprostadil via a targeted perfusion microcatheter was more effective in improving myocardial perfusion in patients undergoing elective PCI than nitroglycerin. Lippincott Williams & Wilkins 2021-04-16 /pmc/articles/PMC8052047/ /pubmed/33847683 http://dx.doi.org/10.1097/MD.0000000000025551 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 3400 Zhang, Weifeng Dai, Jinjie Zheng, Xiaowen Xu, Ke Yang, Xiaoxiao Shen, Lan Wang, Xiaolei Hao, Ziyong Qiu, Xingbiao Jiang, Lisheng Shi, Hongyu Shen, Linghong He, Ben Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial |
title | Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial |
title_full | Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial |
title_fullStr | Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial |
title_full_unstemmed | Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial |
title_short | Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial |
title_sort | myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: a randomized controlled trial |
topic | 3400 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052047/ https://www.ncbi.nlm.nih.gov/pubmed/33847683 http://dx.doi.org/10.1097/MD.0000000000025551 |
work_keys_str_mv | AT zhangweifeng myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT daijinjie myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT zhengxiaowen myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT xuke myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT yangxiaoxiao myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT shenlan myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT wangxiaolei myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT haoziyong myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT qiuxingbiao myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT jianglisheng myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT shihongyu myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT shenlinghong myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial AT heben myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial |